The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Vaccines for preventing pneumococcal infection in adults
Abstract
BACKGROUND: Diseases caused by Streptococcus pneumoniae(S. pneumoniae) continue to cause substantial morbidity and mortality throughout the world. Whilst pneumococcal polysaccharide vaccines (PPV) have the potential to prevent disease and death, the degree of protection afforded against various clinical endpoints and within different populations is uncertain. OBJECTIVES: To assess the effectiveness of PPV in preventing disease or death in adults. Adverse events were not assessed. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, Issue 2); MEDLINE (January 1966 to June 2007); and EMBASE (1974 to June 2007). SELECTION CRITERIA: A) Randomised controlled trials (RCTs) comparing PPV with placebo, control vaccines, or no intervention.B) Non-RCTs assessing PPV effectiveness against invasive pneumococcal disease (IPD). DATA COLLECTION AND ANALYSIS: A) RCTs: trial quality assessment was conducted by two review authors and data extracted by three authors; odds ratios (OR) and 95% confidence intervals (CI) were estimated using a random-effects model.B) Non-RCTs: study quality, including measures to control for confounding, was assessed and data extracted by two review authors; OR and 95% CI were calculated using a random-effects model following the conversion of each study outcome to a log OR and standard error. MAIN RESULTS: Twenty-two studies met our inclusion criteria (15 RCTs involving 48,656 participants and 7 non-RCTs involving 62,294 participants). Meta-analysis of the RCTs found strong evidence of PPV efficacy against IPD with no statistical heterogeneity (OR 0.26, 95% CI 0.15 to 0.46; random-effects model, I-squared (I(2)) = 0%). Efficacy against all cause pneumonia was inconclusive with substantial statistical heterogeneity (OR 0.71, 95% CI 0.52 to 0.97; random-effects model, I(2) = 87.3%). PPV was not associated with substantial reductions in all-cause mortality (OR 0.87, 95% CI 0.69 to 1.10; random-effects model, I(2) = 75.3%). Vaccine efficacy against primary outcomes appeared poorer in adults with chronic illness but the difference was not statistically significant. Non-RCTs provided evidence for protection against IPD in populations for whom the vaccine is currently utilised (OR 0.48, 95% CI 0.37 to 0.61; random-effects model, I(2) = 31.4%). AUTHORS' CONCLUSIONS: This meta-analysis provides evidence supporting the recommendation for PPV to prevent IPD in adults. The evidence from RCTs is less clear with respect to adults with chronic illness. This might be because of lack of effect or lack of power in the studies. The meta-analysis does not provide compelling evidence to support the routine use of PPV to prevent all-cause pneumonia or mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Whitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., Lynfield, R., Reingold, A., Cieslak, P. R., Pilishvili, T., Jackson, D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022823 · Cited by 2,228
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163
The Protective Efficacy of Polyvalent Pneumococcal Polysaccharide Vaccine
Shapiro, E. D., Berg, A. T., Austrian, R., Schroeder, D., Parcells, V., Margolis, A., Adair, R. K., & Clemens, J. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252101 · Cited by 1,051
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations
Butler, J. C. (1993) · JAMA · doi:10.1001/jama.270.15.1826 · Cited by 671
Effectiveness of Pneumococcal Polysaccharide Vaccine in Older Adults
Jackson, L. A., Neuzil, K. M., Yu, O., Benson, P., Barlow, W. E., Adams, A. L., Hanson, C. A., Mahoney, L. D., Shay, D. K., & Thompson, W. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022678 · Cited by 608
PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES
MacLeod, C. M., Hodges, R. G., Heidelberger, M., & Bernhard, W. G. (1945) · Journal of Experimental Medicine · doi:10.1084/jem.82.6.445 · Cited by 518
7. Prevention of Pneumococcal Pneumonia by Vaccination
Austrian, R., Douglas, R. M., Schiffman, G., Coetzee, A. M., Koornhof, H. J., Hayden-Smith, S., & Reid, R. D. W. (1985) · Life with the Pneumococcus · doi:10.9783/9781512800135-009 · Cited by 401
Cited by
Clinical and economic burden of community-acquired pneumonia among adults in Europe
Welte, T., Torres, A., & Nathwani, D. (2012) · Thorax · doi:10.1136/thx.2009.129502 · Cited by 1,033
Vaccines for preventing pneumococcal infection in adults
Moberley, S., Holden, J., Tatham, D. P., & Andrews, R. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000422.pub3 · Cited by 960
Self-citationGuidelines for the management of adult lower respiratory tract infections - Full version
Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03672.x · Cited by 942
Risk factors for community-acquired pneumonia in adults in Europe: a literature review
Torres, A., Peetermans, W. E., Viegi, G., & Blasi, F. (2013) · Thorax · doi:10.1136/thoraxjnl-2013-204282 · Cited by 839
Pneumococcal Capsules and Their Types: Past, Present, and Future
Geno, K. A., Gilbert, G. L., Song, J. Y., Skovsted, I. C., Klugman, K. P., Jones, C., Konradsen, H. B., & Nahm, M. H. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00024-15 · Cited by 732
Effros, R. B., Fletcher, C. V., Gebo, K., Halter, J. B., Hazzard, W. R., Horne, F. M., Huebner, R. E., Janoff, E. N., Justice, A. C., Kuritzkes, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590150 · Cited by 539
Burden of Community-Acquired Pneumonia in North American Adults
File, T. M., & Marrie, T. J. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.03.2130 · Cited by 472
Guidelines for the management of adult lower respiratory tract infections - Summary
Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03602.x · Cited by 468
Efficacy of pneumococcal vaccination in adults: a meta-analysis
Huss, A., Scott, P., Stuck, A. E., Trotter, C., & Egger, M. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080734 · Cited by 414
Effect of vaccines on bacterial meningitis worldwide
McIntyre, P. B., O'Brien, K. L., Greenwood, B., & van de Beek, D. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61187-8 · Cited by 326
Mehta, R. H. (2009) · JAMA · doi:10.1001/jama.2009.600 · Cited by 293
Maruyama, T., Taguchi, O., Niederman, M. S., Morser, J., Kobayashi, H., Kobayashi, T., D'Alessandro-Gabazza, C., Nakayama, S., Nishikubo, K., Noguchi, T., et al. (2010) · BMJ · doi:10.1136/bmj.c1004 · Cited by 279
Ademokun, A., Wu, Y., Martin, V., Mitra, R., Sack, U., Baxendale, H., Kipling, D., & Dunn‐Walters, D. K. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00732.x · Cited by 139
Panagiotou, O. A., Contopoulos-Ioannidis, D. G., & Ioannidis, J. P. A. (2013) · BMJ · doi:10.1136/bmj.f707 · Cited by 89
The Effect of Chronic Cytomegalovirus Infection on Pneumococcal Vaccine Responses
O'Connor, D., Trück, J., Lazarus, R., Clutterbuck, E. A., Voysey, M., Jeffery, K., & Pollard, A. J. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit673 · Cited by 22
Metadata
- Authors
- Moberley, S., Holden, J., Tatham, D. P., & Andrews, R. M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2008-01-23
- Issue
- 1
- Pages
- CD000422-CD000422
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2602921578
- Cited by
- 387
- References
- 68
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.